- Home
- AB vs RLAY Comparison
AB vs RLAY Comparison
Compare AB & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AB | RLAY |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AB | RLAY |
|---|---|---|
| Price | $35.62 | $17.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $40.40 | $19.50 |
| AVG Volume (30 Days) | 340.1K | ★ 3.7M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.59% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.45 | $324.03 |
| P/E Ratio | $13.85 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $35.59 | $3.03 |
| 52 Week High | $44.11 | $17.50 |
Technical Indicators
Market Signals| Indicator | AB | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 32.32 | 71.94 |
| Support Level | $35.59 | $11.68 |
| Resistance Level | $39.51 | N/A |
| Average True Range (ATR) | 0.61 | 0.94 |
| MACD | -0.06 | 0.31 |
| Stochastic Oscillator | 5.22 | 96.65 |
Price Performance
Historical ComparisonAbout AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (41%), and private (18%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of February 2026, the company had $880.0 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (40%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.